S
Stefano Acali
Researcher at Schering-Plough
Publications - 4
Citations - 1456
Stefano Acali is an academic researcher from Schering-Plough. The author has contributed to research in topics: Monoclonal antibody & Antibody. The author has an hindex of 4, co-authored 4 publications receiving 1418 citations.
Papers
More filters
Journal ArticleDOI
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
Elisa Scarselli,Helenia Ansuini,Raffaele Cerino,Rosa Maria Roccasecca,Stefano Acali,Gessica Filocamo,Cinzia Traboni,Alfredo Nicosia,Riccardo Cortese,Alessandra Vitelli +9 more
TL;DR: It is discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81, and the receptor responsible for E2 binding to human hepatic cells is identified as the human scavenger receptor class B type I (SR‐BI).
Journal ArticleDOI
Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2
Rosamaria Roccasecca,Helenia Ansuini,Alessandra Vitelli,Annalisa Meola,Elisa Scarselli,Stefano Acali,Monica Pezzanera,Bruno Bruni Ercole,Jane A. McKeating,Asutosh T. Yagnik,Armin Lahm,Anna Tramontano,Riccardo Cortese,Alfredo Nicosia +13 more
TL;DR: E2 proteins from different isolates displayed a profile of binding to human hepatic cells different from that observed on Molt-4 cells or isolated recombinant CD81, indicating that additional factors are involved in viral recognition by target liver cells.
Journal ArticleDOI
Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer
Helenia Ansuini,Annalisa Meola,Zeynep Gunes,Valentina Paradisi,Monica Pezzanera,Stefano Acali,Claudia Santini,Alessandra Luzzago,Federica Mori,Domenico Lazzaro,Gennaro Ciliberto,Alfredo Nicosia,Nicola La Monica,Alessandra Vitelli +13 more
TL;DR: Data show that in a pancreatic cancer model comparable therapeutic efficacy is obtained either by promoting receptor degradation or by blocking receptor activation.
Journal ArticleDOI
Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration
Zeynep Gunes,Adriana Zucconi,Mario Cioce,Annalisa Meola,Monica Pezzanera,Stefano Acali,Immacolata Zampaglione,Valeria De Pratti,Luca Bova,Fabio Talamo,Anna Demartis,Paolo Monaci,Nicola La Monica,Gennaro Ciliberto,Alessandra Vitelli +14 more
TL;DR: It is shown that distinct properties beside ligand antagonism are required for anti-RON mAbs to exert antitumor effects in vivo, and that the antagonistic antibodies fall into three distinct epitope regions of the RON extracellular Sema domain.